The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review

R L van der Horst; O van der Hel; L Lutgens; M van der Aa; B Slangen; R Kruitwagen; R I Lalisang

doi:10.1016/j.critrevonc.2022.103701

The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review

R L van der Horst^*, O van der Hel, L Lutgens, M van der Aa, B Slangen, R Kruitwagen, R I Lalisang

^*Corresponding author for this work

Research output: Contribution to journal › (Systematic) Review article › peer-review

Abstract

The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. Treatment of FIGO I-II UCS usually consists of surgery with or without adjuvant treatment. Due to the high metastatic potential, aggressive combined modality adjuvant treatment approaches, consisting of chemo- and radiotherapy, have been of interest. Our systematic review aims to compare survival, disease control and toxicity profiles in patients receiving adjuvant chemoradiation to other adjuvant strategies (e.g.observation, chemotherapy or radiotherapy). A total of ten studies were included for a combined cohort size of 6520 patients. Generally, the studies showed a trend towards improved disease control and survival in patients undergoing adjuvant multimodal treatment, although statistical significance was often not reached. Selection bias and non-randomized treatment allocation pose serious challenges to extrapolate these outcomes to clinical practice. We recommend additional prospective research on the role of adjuvant chemoradiation in FIGO I-II UCS.

Original language	English
Article number	103701
Number of pages	10
Journal	Critical Reviews in Oncology/Hematology
Volume	175
Early online date	6 May 2022
DOIs	https://doi.org/10.1016/j.critrevonc.2022.103701
Publication status	Published - Jul 2022

Keywords

Adjuvant chemoradiation
Adjuvant multimodal treatment
ENDOMETRIAL CANCER
Early stage high risk uterine malignancy
FEMALE GENITAL-TRACT
MESODERMAL TUMORS
MIXED MULLERIAN TUMORS
PELVIC IRRADIATION
PHASE-II
PROGNOSTIC-FACTORS
RADIATION-THERAPY
STAGE-I
UTERINE CARCINOSARCOMA
Uterine carcinosarcoma
Uterine mixed mullarian tumor

Access to Document

10.1016/j.critrevonc.2022.103701Licence: CC BY

Cite this

@article{d5a86c78aab04187ac8da887269bea6a,

title = "The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review",

abstract = "The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. Treatment of FIGO I-II UCS usually consists of surgery with or without adjuvant treatment. Due to the high metastatic potential, aggressive combined modality adjuvant treatment approaches, consisting of chemo- and radiotherapy, have been of interest. Our systematic review aims to compare survival, disease control and toxicity profiles in patients receiving adjuvant chemoradiation to other adjuvant strategies (e.g.observation, chemotherapy or radiotherapy). A total of ten studies were included for a combined cohort size of 6520 patients. Generally, the studies showed a trend towards improved disease control and survival in patients undergoing adjuvant multimodal treatment, although statistical significance was often not reached. Selection bias and non-randomized treatment allocation pose serious challenges to extrapolate these outcomes to clinical practice. We recommend additional prospective research on the role of adjuvant chemoradiation in FIGO I-II UCS.",

keywords = "Adjuvant chemoradiation, Adjuvant multimodal treatment, ENDOMETRIAL CANCER, Early stage high risk uterine malignancy, FEMALE GENITAL-TRACT, MESODERMAL TUMORS, MIXED MULLERIAN TUMORS, PELVIC IRRADIATION, PHASE-II, PROGNOSTIC-FACTORS, RADIATION-THERAPY, STAGE-I, UTERINE CARCINOSARCOMA, Uterine carcinosarcoma, Uterine mixed mullarian tumor",

author = "{van der Horst}, {R L} and {van der Hel}, O and L Lutgens and {van der Aa}, M and B Slangen and R Kruitwagen and Lalisang, {R I}",

year = "2022",

month = jul,

doi = "10.1016/j.critrevonc.2022.103701",

language = "English",

volume = "175",

journal = "Critical Reviews in Oncology/Hematology",

issn = "1040-8428",

publisher = "Elsevier Science",

}

TY - JOUR

T1 - The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus

T2 - a systematic review

AU - van der Horst, R L

AU - van der Hel, O

AU - Lutgens, L

AU - van der Aa, M

AU - Slangen, B

AU - Kruitwagen, R

AU - Lalisang, R I

PY - 2022/7

Y1 - 2022/7

N2 - The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. Treatment of FIGO I-II UCS usually consists of surgery with or without adjuvant treatment. Due to the high metastatic potential, aggressive combined modality adjuvant treatment approaches, consisting of chemo- and radiotherapy, have been of interest. Our systematic review aims to compare survival, disease control and toxicity profiles in patients receiving adjuvant chemoradiation to other adjuvant strategies (e.g.observation, chemotherapy or radiotherapy). A total of ten studies were included for a combined cohort size of 6520 patients. Generally, the studies showed a trend towards improved disease control and survival in patients undergoing adjuvant multimodal treatment, although statistical significance was often not reached. Selection bias and non-randomized treatment allocation pose serious challenges to extrapolate these outcomes to clinical practice. We recommend additional prospective research on the role of adjuvant chemoradiation in FIGO I-II UCS.

AB - The uterine carcinosarcoma (UCS) is a rare entity with poor prognosis. Treatment of FIGO I-II UCS usually consists of surgery with or without adjuvant treatment. Due to the high metastatic potential, aggressive combined modality adjuvant treatment approaches, consisting of chemo- and radiotherapy, have been of interest. Our systematic review aims to compare survival, disease control and toxicity profiles in patients receiving adjuvant chemoradiation to other adjuvant strategies (e.g.observation, chemotherapy or radiotherapy). A total of ten studies were included for a combined cohort size of 6520 patients. Generally, the studies showed a trend towards improved disease control and survival in patients undergoing adjuvant multimodal treatment, although statistical significance was often not reached. Selection bias and non-randomized treatment allocation pose serious challenges to extrapolate these outcomes to clinical practice. We recommend additional prospective research on the role of adjuvant chemoradiation in FIGO I-II UCS.

KW - Adjuvant chemoradiation

KW - Adjuvant multimodal treatment

KW - ENDOMETRIAL CANCER

KW - Early stage high risk uterine malignancy

KW - FEMALE GENITAL-TRACT

KW - MESODERMAL TUMORS

KW - MIXED MULLERIAN TUMORS

KW - PELVIC IRRADIATION

KW - PHASE-II

KW - PROGNOSTIC-FACTORS

KW - RADIATION-THERAPY

KW - STAGE-I

KW - UTERINE CARCINOSARCOMA

KW - Uterine carcinosarcoma

KW - Uterine mixed mullarian tumor

U2 - 10.1016/j.critrevonc.2022.103701

DO - 10.1016/j.critrevonc.2022.103701

M3 - (Systematic) Review article

C2 - 35533817

SN - 1040-8428

VL - 175

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

M1 - 103701

ER -

The role of multimodal adjuvant therapy for FIGO I-II carcinosarcoma of the uterus: a systematic review

Abstract

Keywords

Access to Document

Fingerprint

Cite this